跳至主要内容
临床试验/NCT00417716
NCT00417716撤回3 期

The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Asociación para Evitar la Ceguera en México1 个研究点 分布在 1 个国家开始时间: 2005年9月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
撤回
发起方
试验地点
1
主要终点
BCVA

研究概览

简要总结

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema

详细描述

A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up) pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein angiography was evaluated at months 1 and 3.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes
  • Macular edema involving the center of the macula demonstrated on OCT
  • Clear ocular media
  • Untreated patients
  • Older than 45 years
  • BCVA of the fellow eye at least 20/100

排除标准

  • Renal diabetic disease, uncontrolled hypertension or stroke history
  • Other ocular disease
  • Ocular surgery excepting uncomplicated phacoemulsification
  • History of photocoagulation (panretinal or focal)
  • History of another intravitreal treatment (like triamcinolone)

结局指标

主要结局

BCVA

Fluorescein Angiography

Optical Coherence Tomography

次要结局

未报告次要终点

研究者

发起方
Asociación para Evitar la Ceguera en México
申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Use of Intravitreal Bevacizumab in Patients With... | 临床试验